Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,654 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain.
Puente J, Pinto A, Mendez-Vidal MJ, García Del Muro X, Maroto P, Vazquez S, Luque-Caro R, Anido U, Strunz-McKendry T, Upadhyay A, Montes J, Ortiz Nuñez A, González Portela J, Castellano D. Puente J, et al. Among authors: pinto a. Clin Transl Oncol. 2024 Oct 4. doi: 10.1007/s12094-024-03734-8. Online ahead of print. Clin Transl Oncol. 2024. PMID: 39365365
Retrospective study assessing the role of the androgen receptor in clear cell renal cell cancer patients treated with VEGFR inhibitors in monotherapy.
Osorio L, Grazioso TP, de Velasco G, Etxaniz O, Pérez-Gracia JL, Pinto Á, Durán I, Grande E, Garcia PB, Lázaro M, Rodriguez L, Villalobos ML, García L, Cuellar A, Solís-Hernández MP, Pernaut C, Rodríguez-Moreno JF, Rodriguez-Antona C, García-Donas J. Osorio L, et al. Among authors: pinto a. Clin Transl Oncol. 2024 Oct 4. doi: 10.1007/s12094-024-03652-9. Online ahead of print. Clin Transl Oncol. 2024. PMID: 39365364
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study.
Rizzo M, Soares A, Grande E, Bamias A, Kopp RM, Lenci E, Buttner T, Salah S, Grillone F, de Carvalho IT, Tapia JC, Gucciardino C, Pinto A, Mennitto A, Abahssain H, Rescigno P, Myint Z, Takeshita H, Spinelli GP, Popovic L, Vitale MG, Fiala O, Giannatempo P, Zakopoulou R, Carrozza F, Massari F, Monteiro FSM, Pace MP, Giannini M, Roviello G, Porta C, Battelli N, Kanesvaran R, Santoni M. Rizzo M, et al. Among authors: pinto a. Sci Rep. 2024 Aug 27;14(1):19802. doi: 10.1038/s41598-024-70182-3. Sci Rep. 2024. PMID: 39187558 Free PMC article.
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
Massari F, Santoni M, Takeshita H, Okada Y, Tapia JC, Basso U, Maruzzo M, Scagliarini S, Büttner T, Fornarini G, Myint ZW, Galli L, Souza VC, Pichler R, De Giorgi U, Gandur N, Lam ET, Gilbert D, Popovic L, Grande E, Mammone G, Berardi R, Crabb SJ, Kemp R, Molina-Cerrillo J, Freitas M, Luz M, Iacovelli R, Calabrò F, Tural D, Atzori F, Küronya Z, Chiari R, Campos S, Caffo O, Fay AP, Kucharz J, Zucali PA, Rinck JA, Zeppellini A, Bastos DA, Aurilio G, Mota A, Trindade K, Ortega C, Sade JP, Rizzo M, Fiala O, Vau N, Giannatempo P, Barillas A, Monteiro FSM, Dauster B, Mennitto A, Nogueira L, de Carvalho Fernandes R, Seront E, Aceituno LG, Grillone F, Cutuli HJ, Fernandez M, Bassanelli M, Kopp RM, Roviello G, Abahssain H, Procopio G, Milella M, Kopecky J, Martignetti A, Messina C, Caitano M, Inman E, Kanesvaran R, Herchhorn D, Santini D, Bamias A, Bisonni R, Mosca A, Morelli F, Maluf F, Soares A, Nunes F, Pinto A, Zgura A, Incorvaia L, Ansari J, Zabalza IO, Landmesser J, Rizzo A, Mollica V, Marchetti A, Rosellini M, Sorgentoni G, Battelli N, Buti S, Porta C, Bellmunt J. Massari F, et al. Among authors: pinto a. Cancer Immunol Immunother. 2024 Apr 18;73(6):106. doi: 10.1007/s00262-024-03682-w. Cancer Immunol Immunother. 2024. PMID: 38634928 Free PMC article.
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study.
Fiala O, Massari F, Basso U, Giannatempo P, Grande E, Buti S, Myint ZW, De Giorgi U, Pichler R, Grillone F, Ürün Y, Calabrò F, Bourlon MT, Galli L, Kanesvaran R, Roviello G, Kucharz J, Rizzo M, Park SH, Cerbone L, Seront E, Messina C, Molina-Cerrillo J, Santini D, Yano A, Incorvaia L, Catalano M, Pinto A, Formisano L, Soares A, Facchini G, Fornarini G, Poprach A, Rebuzzi SE, Nasso C, Spinelli GP, Angel M, Stellato M, Tural D, Aurilio G, Epstein I, Carrozza F, Monteiro FSM, Benedetti G, Büchler T, Ortega C, Zakopoulou R, Battelli N, Porta C, Bellmunt J, Gupta S, Santoni M. Fiala O, et al. Among authors: pinto a. Target Oncol. 2024 Nov;19(6):905-915. doi: 10.1007/s11523-024-01099-0. Epub 2024 Oct 1. Target Oncol. 2024. PMID: 39354179 Free PMC article.
Inflammatory discoveries two years after acute severe COVID-19: a longitudinal biomarker profile assessment in long COVID individuals in the Brazilian Amazon.
Maciel ABS, Pinto AS, Maia Silva B, Goulart CL, Silva LFA, Chaves AS, Mouta GS, Sato CMS, Valente J, Mwangi VI, de Melo GC, Monteiro W, Lacerda M, Arêas GPT, Sampaio VS, Costa AG, Almeida-Val F. Maciel ABS, et al. Among authors: pinto as. Front Immunol. 2024 Dec 23;15:1520193. doi: 10.3389/fimmu.2024.1520193. eCollection 2024. Front Immunol. 2024. PMID: 39763676 Free PMC article.
4,654 results